- Home
- A-Z Publications
- Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
- Previous Issues
- Volume 8, Issue 5, 2008
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) - Volume 8, Issue 5, 2008
Volume 8, Issue 5, 2008
-
-
Editorial [Hot Topic: Tyrosine Kinase Inhibitors in Cancer Therapy (Guest Editor: S. Eckhardt)]
By S. EckhardtThe revolutionary discovery of the human genom opened novel approaches for understanding the malignant process. It is now generally accepted, that the neoplastic tissue is the result of a multistep genetic event induced by inherited and environmental factors. Each tumor cell is characterized by specific mutations. These genetic alterations are promising targets for inhibitory substances. Thus, such agents may be useful in can Read More
-
-
-
Antiangiogenic Drugs and Tyrosine Kinases
Authors: Jozsef Timar and Balazs DomeVarious cancer types have different molecular and biological strategies for vascularization: neoangiogenesis, postnatal vasculogenesis, glomeruloid angiogenesis, intussusceptive microvascular growth, vessel cooption and vascular mimicry. The majority is still relatively obscure, which limits the development of more successful antivascular agents. It is not a surprise that, as our knowledge is deepest in case of tumor-induced neo Read More
-
-
-
Novel Molecular-Targeted Therapeutics for the Treatment of Cancer
Authors: Hiroshi Yasui and Kohzoh ImaiRecently, intensive laboratory and preclinical studies have identified and validated therapeutic molecular targets in cancer, particularly the receptor tyrosine kinases, the intracellular pathways, and the genetic and epigenetic alterations, resulting in an unprecedented surge of novel, targeted therapies and therapeutic regimens. There are currently over 30 new agents being tested in the treatment of solid tumors as well as he Read More
-
-
-
Inhibition of Receptor Tyrosine Kinases in Combination with Chemotherapy for the Treatment of Breast Cancer
Authors: S. L. Moulder, B. S. Craft and G. N. HortobagyiAlthough significant advances have been made in the treatment of breast cancer using chemotherapy, less than half of the patients treated for localized breast cancer benefit from adjuvant chemotherapy and most patients with metastatic cancer eventually develop disease that is chemotherapy resistant. Targeted agents, such as inhibitors of tyrosine kinases, offer the opportunity to reverse chemotherapy resistan Read More
-
-
-
HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?
HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination with chemotherapy, has shown significant clinical benefit in improving survival in metastatic patients, as well as halving the recurrence rate and improving survival in early breast Read More
-
-
-
New Trends in Molecular Imaging of Tumor Angiogenesis
Authors: Thomas Berthelot, Marie-Claire Lasne and Gerard DelerisTumor development leading to cancer is a complex process involving several steps. Among them, angiogenesis, ie growth of new tumor induced blood vessels is one of the most important therapeutic targets in the search for anticancer agents. One point which remain to be addressed is the detection of tumor angiogenic areas, ie tumor angiogenesis imaging. After presenting the key points of tumor development which lead t Read More
-
-
-
Monoclonal Antibodies in Clinical Oncology
Authors: S. Dalle, C. Thieblemont, L. Thomas and C. DumontetMonoclonal antibodies have yet considerably modified the field of clinical oncology. The growing knowledge of key cellular pathways in tumor induction and progression, targeted therapies represent an increasing proportion of new drugs entering clinical trials. Some molecules such as trastuzumab, rituximab, alemtuzumab, cetuximab are now widely used in clinical practice. These antibodies are now tested in different i Read More
-
-
-
Targeting Inhibitor of Apoptosis Proteins (IAPs) for Cancer Therapy
By Simone FuldaSince cell death by apoptosis plays a key role in the regulation of tissue homeostasis, dysregulation of the cell's intrinsic death program may foster tumor formation and progression. “Inhibitor of apoptosis proteins” (IAPs) block apoptosis at the core of the apoptotic machinery by inhibiting effector caspases. Aberrant expression and/or function of IAPs are found in many human cancers and have been implied in resistance t Read More
-
-
-
Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Authors: Amazia Zimber and Christian GespachBile acids, their physiology and metabolism, their role in carcinogenesis and other major human diseases are recently undergoing significant progress. Starting in 1999 when the orphan nuclear receptor FXR was shown to be specifically activated by bile acids, these compounds became part of the arsenal of ligands of the steriod hormone superfamily of nuclear receptors, including receptors of Vitamin D3, retinoids (RAR, Read More
-
-
-
p53 Targeting Can Enhance Cancer Therapy via Radiation, Heat and Anti-Cancer Agents
Authors: Takeo Ohnishi, Akihisa Takahashi, Eiichiro Mori and Ken OhnishiIn recent years, genes associated with cancer have been studied to assess their possible use as predictive indicators for cancer therapies. Among these, the gene product of the tumor suppressor gene p53 was found to play an important role in cancer therapy. The p53 molecule induces cell-cycle arrest, apoptosis and DNA repair after cells are subjected to cancer therapies involving radiation, heat and various anti-cancer age Read More
-
-
-
Hyperthermia Associated Osteonecrosis in Young Patients with Pelvic Malignancies
Authors: Marcus Jager, Stefan Balzer, Rudiger Wessalowski, J. Schaper, Ulrich Gobel, Xinning Li and Rudiger KrauspeIntroduction: Progressive and non-juvenile avascular osteonecrosis (AVN) is a rare condition in children. During the last decade, some data indicate that regional deep hyperthermia therapy (RHT) combined with either chemo- and / or radiotherapy in malignancies is associated with AVN in young patients. In this study, we present our data on AVN following RHT in children with intra-pelvic malignancies. Material and Methods: Locali Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
Most Read This Month
Article
content/journals/acamc
Journal
10
5
false
en
